CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
The new online Learning Center with new content can still be found under the “Training” folder on ...